[go: up one dir, main page]

AU2003230834A1 - Antagonists of il-21 and modulation of il-21-mediated t cell responses - Google Patents

Antagonists of il-21 and modulation of il-21-mediated t cell responses

Info

Publication number
AU2003230834A1
AU2003230834A1 AU2003230834A AU2003230834A AU2003230834A1 AU 2003230834 A1 AU2003230834 A1 AU 2003230834A1 AU 2003230834 A AU2003230834 A AU 2003230834A AU 2003230834 A AU2003230834 A AU 2003230834A AU 2003230834 A1 AU2003230834 A1 AU 2003230834A1
Authority
AU
Australia
Prior art keywords
antagonists
mediated
modulation
cell responses
responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003230834A
Other versions
AU2003230834A8 (en
Inventor
Thomas Moll
Terry B. Strom
Xin Xiao Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2003230834A1 publication Critical patent/AU2003230834A1/en
Publication of AU2003230834A8 publication Critical patent/AU2003230834A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003230834A 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses Abandoned AU2003230834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37103802P 2002-04-09 2002-04-09
US60/371,038 2002-04-09
PCT/US2003/010736 WO2003087320A2 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Publications (2)

Publication Number Publication Date
AU2003230834A1 true AU2003230834A1 (en) 2003-10-27
AU2003230834A8 AU2003230834A8 (en) 2003-10-27

Family

ID=29250623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003230834A Abandoned AU2003230834A1 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Country Status (2)

Country Link
AU (1) AU2003230834A1 (en)
WO (1) WO2003087320A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
AU2003243415A1 (en) 2002-06-07 2003-12-22 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
RU2005113992A (en) * 2002-10-11 2005-10-27 Ново Нордиск А/С (DK) TREATMENT OF ALLERGIC CONDITIONS USING IL-21
CA2501807A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
RU2354703C2 (en) 2002-12-13 2009-05-10 Займодженетикс, Инк. Producing il-21 in prokaryotic host cells
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
CN102516386A (en) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21 derivatives
EP1708737A2 (en) * 2004-01-15 2006-10-11 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
EP1586585A1 (en) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expression system for the production of IL-15/Fc fusion proteins and their use
WO2006135385A2 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
ITRM20040586A1 (en) * 2004-11-29 2005-02-28 Giuliani Spa ANTIGENIC EPITOPES OF INTERLEUCHINA-21, RELATIVE ANTIBODIES AND THEIR USE IN MEDICAL FIELD.
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
RU2412199C2 (en) 2005-04-18 2011-02-20 Ново Нордиск А/С Versions of il-21
CA2632218A1 (en) 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
PL1963369T3 (en) 2005-11-28 2013-10-31 Zymogenetics Inc Il-21 antagonists
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
EP2109620B1 (en) * 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
EP2406282A1 (en) * 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
CN102071191A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
CN102071192A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA used for curing psoriasis
CN102071198A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
SI2665486T1 (en) 2011-01-18 2020-07-31 Bioniz, Llc Compositions for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CN105198999A (en) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 Fusion protein and its preparation method and use
PT3359556T (en) 2015-10-09 2021-08-30 Bioniz Llc Modulating gamma - c -cytokine activity
KR101928981B1 (en) * 2016-09-02 2018-12-13 고려대학교 산학협력단 Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
CN111205361B (en) * 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 Interleukin 21 protein (IL21) mutant and application thereof
BR112021021878A2 (en) 2019-05-03 2022-01-18 Bioniz Llc Modulation of gamma-c-cytokine signaling effects for treatment of alopecia and associated disorders
US20250000946A1 (en) * 2021-09-26 2025-01-02 WuXi Biologics Ireland Limited Il-2 variants and fusion proteins thereof

Also Published As

Publication number Publication date
WO2003087320A3 (en) 2004-08-26
AU2003230834A8 (en) 2003-10-27
WO2003087320A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AU2003230834A1 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003295801A1 (en) MODULATION OF HIF1Alpha AND HIF2Alpha EXPRESSION
AU2003288902A1 (en) Microcapsules and methods of use
AU2003281736A1 (en) Electrodes and related devices
AU2003290986A1 (en) Power converter circuitry and method
AU2003217870A1 (en) Pini-modulating compounds and methods of use thereof
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003286446A1 (en) Sheet dispensers and methods of making and using the same
AU2003244896A1 (en) E-learning station and interface
AU2003218437A1 (en) Alkali-iron-cobalt phosphates and related electrode active materials
AU2003220558A1 (en) Amide compounds and methods of using the same
AU2003259717A1 (en) Modulators of rabggt and methods of use thereof
AU2003233069A1 (en) Gel and powder making
AU2003211585A1 (en) Reaction cell and method of using the cell
AU2003256710A1 (en) Auto-stimulating cells and method for making and using the same
AU2003298020A1 (en) Catalytic antioxidants and methods of use
AU2003235193A1 (en) Endocrine cell lines and method of using the same
AU2003209180A1 (en) Battery and method of packaging
AU2003216840A1 (en) Transdifferentiation of cells and tissues
AU2003297924A1 (en) Electrode assembly and method of using the same
AU2003297612A1 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003287802A1 (en) Palpometer and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase